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Carvedilol is a novel, multiple-action cardiovascular drug that is currently approv-
ed in many countries for the treatment of hypertension. The reduction in blood pressure
produced by carvedilol results primarily from beta-adrenoceptor blockade and vasodi-
lation, the latter resulting from alpha 1-adrenoceptor blockade. These actions as well as
several other carvedilol activities are associated with cardioprotection in animal models
that occurs to a degree that is greater than that observed with other drugs. The multiple
actions of carvedilol may also provide the underlying rationale for the use of the drug in
the treatment of coronary artery disease and congestive heart failure (1).
Carvedilol is well absorbed from the gastrointestinal tract but is subject to consider-
able first-pass metabolism in the liver; its absolute bioavailability is about 25%. It has a
half-life of 2.2 ± 0.3 h; longer half-lives of about 6 h have been measured at lower con-
centrations (2, 3).
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Transdermal patches of carvedilol with a HPMC-drug
reservoir were prepared by the solvent evaporation tech-
nique. In this investigation, the membranes of Eudragit
RL100 and Eudragit RS100 were cast to achieve control-
led release of the drug. The prepared patches possessed
satisfactory physicochemical characteristics. Thickness,
mass and drug content were uniform in prepared batch-
es. Moisture vapour transmission through the patches
followed zero-order kinetics. In vitro permeation studies
were performed using a K-C diffusion cell across hairless
guinea pig skin and followed the super case II transport
mechanism. The effects of non-ionic surfactants Tween 80
and Span 80 on drug permeation were studied. The non-
-ionic surfactants in the patches increased the permeati-
on rate, Span 80 exhibiting better enhancement relative
to Tween 80. The patches were seemingly free of poten-
tially hazardous skin irritation.
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Carvedilol was chosen as the model candidate for this study since it possesses near
ideal characteristics that a drug must have in formulating a transdermal drug delivery
system: low molecular mass, high lipid solubility, effective in low plasma concentration
as well as a high degree of first-pass metabolism. It also means multiple daily adminis-
tration with subsequent lack of patient compliance. The aim of this study was to deve-
lop and evaluate transdermal patches of carvedilol so as to prevent its first-pass metabo-
lism and achieve controlled release.
EXPERIMENTAL
Material and methods
Carvedilol was a gift from Sun Pharmaceutical Industries Ltd. (India). Eudragit
RL100 was kindly supplied by Intas Lab. Pvt. Ltd. (India). Torrent Research Centre (In-
dia) donated Eudragit RS100. Polyvinyl pyrrolidone K30, propylene glycol, Span 80 and
Tween 80 were purchased from Otto Kemi Ltd. (India). All the other chemicals were of
analytical grade.
Drug partition coefficient
The partition coefficient study was performed using n-octanol as the oil phase and
phosphate buffer pH 7.4 as the aqueous phase. The two phases were mixed in equal
quantities and were saturated with each other on a mechanical water bath shaker at 37 °C
for 24 h. The saturated phases were separated by centrifugation at 2000 rpm. Standard
plots of the drug were prepared from both phosphate buffer pH 7.4 and n-octanol. Equal
volumes (10 mL) of the two phases were placed in hexaplicate in conical flasks and, to
each, 100 mg of drug was added. The flasks were shaken at 37 °C for 6 h to achieve com-
plete partitioning at 100 rpm. The two phases were separated by centrifugation at 1000
rpm for 5 min and were then analyzed for respective drug contents (4).
Preparation of patches
Transdermal patches containing carvedilol were prepared by the solvent evapora-
tion technique in cylindrical glass molds with both sides open (5). The bottom of the
mold was wrapped with aluminum foil, on which the backing membrane was cast by
pouring a 4% (m/V) polyvinyl alcohol (PVA) solution followed by drying at 60 °C for 6 h.
The drug reservoir was prepared by dissolving hydroxyl propyl methyl cellulose (HPMC)
in distilled water. Propylene glycol 30% (m/m) of polymer composition was used as a
plasticizer. The drug 0.292% (m/V) (in 5 mL methanol) was added into the homogene-
ous dispersion under slow stirring with a magnetic stirrer. The uniform dispersion was
cast on a PVA backing membrane and dried at 45 °C for 6 h. The rate-controlling mem-
brane was cast on the drug reservoir using 2% (m/V) of Eudragit RL100 (ERL) or Eu-
dragit RS100 (ERS) with 0.10% (m/V) of polyvinyl pyrrolidone K30 (PVP) in dichloro-
methane and 30% (m/m) propylene glycol. 1% (m/V) of permeation enhancer (Tween 80,
Span 80) was incorporated in the drug reservoir of formulations T-4, T-5, T-6 and T-7
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(Table I). The films were cut into small patches (3.14 cm2) containing 3.25 mg of carve-
dilol and stored between sheets of wax paper in a desiccator.
Evaluation of patches
Thickness. – The thickness of patches was measured at three different places using a
micrometer (Mitutoyo Co., Japan) and mean values were calculated (6).
Mass variation. – The patches were subjected to mass variation by individually weigh-
ing 10 randomly selected patches. Such determinations were carried out for each formu-
lation (7).
Folding endurance. – This was determined by repeatedly folding one film at the same
place till it broke. The number of times the film could be folded at the same place with-
out breaking/cracking gave the value of folding endurance (8).
Moisture vapour transmission (MVT). – MVT is defined as the quantity of moisture
transmitted through unit area of film in unit time (9). Glass cells were filled with 2 g of
anhydrous calcium chloride and a film of specified area was affixed onto the cell rim.
The assembly was accurately weighed and placed in a humidity chamber (80 ± 5% RH)
at 27 ± 2 °C for 24 h.
Drug content uniformity. – Patches of specified area (3.14 cm2) were dissolved in 5 mL
of dichloromethane and the volume was made up to 10 mL with phosphate buffer pH
7.4; dichloromethane was evaporated using a rotary vacuum evaporator at 45 °C. A blank
was prepared using a drug-free patch treated similarly. The solutions were filtered through
a 0.45-µm membrane, diluted suitably and absorbances were read at 242 nm in a double
beam UV-Vis spectrophotometer (Thermospectronic-1, UK).
In vitro permeation studies. – Films measuring 3.14 cm2 were subjected to an in vitro
permeation study using a modified Keshary-Chien diffusion cell (cell capacity 75 mL).
Male guinea pigs (Hartley strain, n = 5 for each formulation), each weighing 250 to 300 g
and 6 months of age were used in the present study. They were housed in cages in the
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T-1 PVA HPMC – –
T-2 PVA HPMC ERS –
T-3 PVA HPMC ERL –
T-4 PVA HPMC ERS Tween 80
T-5 PVA HPMC ERS Span 80
T-6 PVA HPMC ERL Tween 80
T-7 PVA HPMC ERL Span 80
PVA – polyvinyl alcohol, HPMC – hydroxypropyl methylcellulose, ERL – Eudragit RL100, ERS – Eudragit RS100
a With carvedilol (0.292%, m/V).
b With PVP (0.1%, m/V).
animal house under controlled temperature (27 ± 2 °C) and light conditions. They were
fed a standard laboratory diet; water was provided ad libitum. Guinea pigs were killed
by cervical dislocation and dorsal skin was removed. After removing the epidermal hairs
and subcutaneous fat, the skin was thoroughly washed and placed overnight in contact
with the receptor phase, phosphate buffer pH 7.4 (10, 11).
Guinea pig dorsal skin was clamped between the donor and recipient compartments.
The film was placed in the donor compartment over the skin and covered with parafilm.
The temperature of receptor phase was maintained at 37 ± 1 °C throughout the experi-
ment. The compartment was in contact with the ambient environment. The amount of
drug permeated through guinea pig skin was determined by withdrawing samples of 1 mL
at predetermined time intervals and replacing them with an equal volume of prewarm-
ed buffer (37 ± 1 °C). The samples were analyzed for drug content at 242 nm.
Primary skin irritancy studies. – Albino rabbits of either sex, each weighing 1.5 to 2.0 kg
and 24 months of age were used in this study (n = 5 in each group). They were housed in
cages in the animal house under controlled temperature (27 ± 2 °C) and light conditions.
They were fed a standard laboratory diet; water was provided ad libitum. The dorsal sur-
face of the rabbits was cleared and the hairs were removed by shaving. The skin was
cleared with rectified spirit. The patches were applied to the shaved skin of rabbits and
secured using adhesive tape USP (LeucoplastTM). On one side of the back, a control patch
(without any drug, group I) and on the other side an experimental patch (group II) were
secured. A 0.8% (V/V) aqueous solution of formaldehyde was applied as a standard irri-
tant (group III) and its effect was compared with test. The animals were observed for
any sign of erythema or oedema for a period of 7 days and scored as reported by Draize
et al. (12).
Ethical clearance for the handling of experimental animals was obtained from the
institutional animal ethical committee (IAEC) formed for this purpose.
RESULTS AND DISCUSSION
n-Octanol and in vitro study fluid (here phosphate buffer, pH 7.4) are considered to
be the standard system for determining the drug partition coefficient between skin and
in vitro fluid (4). The logarithmic value of the partition coefficient (log P) was found to
be 0.79 ± 0.03. The results obtained indicate that the drug possesses sufficient lipophi-
licity, which meets the requirements of formulating it into a transdermal patch.
In the present study, transdermal patches of carvedilol were formulated using the
hydrophilic polymer matrix of hydroxyl propyl methyl cellulose and the effect of Eu-
dragit RL100 and Eudragit RS100 as rate-controlling membrane was studied. The pre-
pared patches were characterized for physicochemical properties, in vitro permeation
profile across excised hairless guinea pig skin and skin irritation studies in albino rab-
bits.
The physicochemical properties of carvedilol transdermal patches are presented in
Table II. The thickness of patches varied from 81.5 ± 0.01 to 96.8 ± 0.0 µm (n = 5); casting
of the rate-controlling membrane increased the thickness. The mass was found to be uni-
form in the prepared batches and varied from 38.1 ± 0.0 to 79.1 ± 0.01 mg per patch. The
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folding endurance measures the ability of patch to withstand rupture; folding endur-
ance was in the range of 302.7 ± 7.4 to 339.4 ± 2.3 (n = 5); patch T-1 representing the least
value. The patch formulated with HPMC alone showed maximum MVT of 0.168 ± 0.004
mg cm–2 h–1, which can be attributed to the hydrophilic nature of the polymer. The cast-
ing of the HPMC-drug reservoir with the rate-controlling membrane of Eudragit RS100
decreased the values of the moisture vapour transmission rate. Incorporation of non-ionic
surfactant in the patches increased the MVT. The MVT through the patches followed a
pattern close to zero-order kinetics. For various formulations, the drug content was be-
tween 3.24 ± 0.01 to 3.25 ± 0.02 mg per patch. The drug content analysis of the prepared
formulations has shown that the process employed to prepare patches in this study was
capable of giving films with a uniform drug content and minimum batch variability.
Release of the drug from transdermal patches is controlled by the chemical proper-
ties of the drug and delivery form, as well as physiological and physicochemical proper-
ties of the biological membrane. In vitro permeation studies are predictive of in vivo per-
formance of a drug. In this study, different formulations released variable amounts of
carvedilol through guinea pig skin in the in vitro fluid. To examine the drug permeation
kinetics and mechanism, the data were fitted to models representing zero-order, first-or-
der and Korsmeyer-Peppas (13, 14). Drug permeation profiles from different formula-
tions are shown in Fig. 1. It was found that 95.1% of drug was released within 9 h from
T-1 (without the rate-controlling membrane) and followed first-order kinetics. This means
the patch is to be applied several times a day. Therefore rate-controlling membranes of
Eudragit RL100 and Eudragit RS100 with PVP were cast with the aim to achieve con-
trolled release of carvedilol from drug reservoirs of HPMC. The cumulative amount of
drug permeated after 24 h from T-2 (ERS as the rate-controlling membrane) and T-3 (ERL
as the rate-controlling membrane) was found to be 64.5 and 66.4%, respectively. Two
surfactants differing in their hydrophile-lipophile balance (HLB) number were therefore,
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Table II. Evaluation of transdermal patchesa
Parameter T-1 T-2 T-3 T-4 T-5 T-6 T-7
Thickness (µm) 81.5±0.01 90.1±0.01 90.8±0.0 96.2±0.0 96.8±0.0 93.3±0.0 93.9±0.0
Mass of 2.0 cm
diameter discs
(mg)
38.1±0.0 64.9±0.03 72.3±0.1 69.5±0.03 68.5±0.0 79.1±0.01 77.4±0.03
Folding
endurance
302.7±7.4 324.3±5.0 339.4±2.3 320.1±4.0 319.0±5.2 334.1±7.4 331.0±5.4
MVT in 24 h
(mg cm–2 h–1)
0.168±0.004 0.132±0.001 0.115±0.002 0.141±0.007 0.149±0.005 0.123±0.003 0.130±0.005
Drug content
(mg per patch)




3.18±0.01 0.87±0.02 0.98±0.01 0.93±0.01 1.19±0.01 1.03±0.02 1.32±0.01
a Results are expressed as mean ± SD (n = 5).
considered. The non-ionic surfactants Tween 80 (HLB = 15.0) and Span 80 (HLB = 4.3)
were incorporated in the patches to enhance the drug permeation across guinea pig skin.
In vitro permeation studies of patches with enhancers indicate that 66.9, 80.3, 72.9 and
89.8% of the drug permeated at the end of 24 h from T-4, T-5 (ERS as the rate-controlling
membrane), T-6 T-7 (ERL as the rate-controlling membrane), respectively. There was im-
provement in the drug permeability across guinea pig skin in the formulations containing
a permeation enhancer. Permeation rates of the patches with non-ionic surfactants were
about 1–1.5 fold higher than in those without enhancers. The permeation rate for formu-
lations T-4 to T-7 was in the range 0.929–1.322 mg cm–2 h–1. The highest permeation rate
was observed in the patches containing Span 80, followed by the patches containing
Tween 80. The effectiveness of permeation enhancers was determined by comparing drug
flux in the presence and absence of each enhancer and their ratio was defined as the en-
hancement factor (13). The non-ionic surfactant Span 80 showed the best enhancement
with an enhancement ratio of 1.35 and 1.38 for patches T-5 (ERS as the rate-controlling
membrane) and T-7 (ERL as the rate-controlling membrane), respectively. The presence
of Tween 80 in the patches also enhanced the permeation rate but to a lesser extent, with
enhancement ratio of 1.05 and 1.22 for T-4 and T-6, respectively. Span 80, which was of
the lower HLB number, was more effective than Tween 80 in increasing the solubility,
and thereby increasing the permeation rate of carvedilol. These results indicate that the
nature of the enhancer head group greatly influences cutaneous barrier impairment. The
more hydrophobic surfactant Span 80 enhanced the carvedilol skin penetration probably
due to changes in the barrier properties of the skin and in the vehicle-stratum corneum
partition coefficient.
The kinetic parameters of drug permeation for different formulations are presented
in Table III. The zero-order plots of T-2, T-3, T-4, T-5, T-6 and T-7 were found to be fairly
linear, as indicated by their high regression values. Therefore it was ascertained that the
drug permeation from these formulations could follow either near zero or zero-order ki-
netics. Hence, to confirm the exact mechanism of drug permeation from these patches,
the data were fitted according to the Korsmeyer-Peppas model (14). Korsmeyer et al. used
a simple empirical equation to describe the general solute release behaviour from con-
trolled release polymer matrices:
mt/mT = k tn
where mt/mT is the fraction of drug released, k is the kinetic constant, t is release time
and n is the diffusional exponent for drug release. Peppas stated that the above equation
could adequately describe the release of solutes from slabs, spheres, cylinders and discs,
regardless of the release mechanism (14, 15). The value of n gives an indication of the re-
lease mechanism: when n = 1, the release rate is independent of time (zero-order) (case II
transport), n = 0.5 stands for Fickian diffusion and when 0.5 < n < 1.0, diffusion and
non-Fickian transport are implicated. Lastly, when n > 1.0, super case II transport is ap-
parent. n is the slope value of log mt/mT vs. the log time curve (16).
In the present study, the coefficient of determination (R2) was found to be much
closer to 1 for the Korsmeyer-Peppas equation. Slope values (n > 1.0) suggest that the
drug permeation from transdermal patches (T-2 to T-7) followed the super case II trans-
port mechanism, possibly owing to chain disentanglement and swelling of hydrophilic
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polymer, HPMC. Formulation T-7 with ERL as the rate-controlling membrane and Span
80 was found to be better, since constant and about 90% of the drug permeation was ob-
served up to 24 h. The higher proportion of quaternary ammonium groups in ERL re-
sulted in rapid hydration and drug release, whereas the lower proportion of ammonium
groups in ERS is responsible for prolonged release of carvedilol (17).
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Table III. Kinetics of in vitro carvedilol permeation across guinea pig skin from transdermal patches
Code
Zero-order First-order Korsmeyer-Peppas
k0 (mg h–1) R2 k1 (h–1) R2 n R2
T-1 0.327 0.963 –0.130 0.990 0.660 0.957
T-2 0.088 0.990 –0.018 0.962 1.098 0.999
T-3 0.094 0.982 –0.022 0.974 1.118 0.993
T-4 0.099 0.991 –0.020 0.969 1.082 0.996
T-5 0.121 0.991 –0.031 0.961 1.206 0.998
T-6 0.104 0.990 –0.024 0.986 1.080 0.997





































Fig. 1. In vitro permeation pro-
files of carvedilol through ex-
cised hairless guinea pig skin
(mean ± SD, n = 5).
Patches T-4, T-5, T-6 and T-7 were subjected to skin irritation studies. No signs of ery-
thema, oedema or ulceration were observed on the skin of albino rabbits after 7 days.
CONCLUSIONS
Transdermal patches consisting of the HPMC-drug reservoir with Span 80 as per-
meation enhancer and rate-controlling membranes of Eudragit RS100 and Eudragit RL100
demonstrated sustained and controlled release of the drug across guinea pig skin during
in vitro permeation studies. Further, their potential to improve carvedilol bioavailability
in humans needs to be investigated in further studies.
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S A @ E T A K
Priprava i vrednovanje transdermalnih flastera karvedilola
YUVERAJ SINGH TANWAR, CHETAN SINGH CHAUHAN i ANSHU SHARMA
Metodom evaporacije otapala pripravljeni su transdermalni flasteri karvedilola s
HPMC-lijek rezervoarom, s membranama od Eudragita RL100 i Eudragita RS100 koje
kontroliraju osloba|anje. Flasteri su bili zadovoljavaju}ih fizi~ko-kemijskih svojstava,
ujedna~ene debljine, mase i sadr`aja ljekovite tvari. Prijelaz vlage i pare kroz flastere
slijedio je kinetiku nultog reda. In vitro permeacija pra}ena je na ko`i zamorca pomo}u
K-C difuzijske }elije, a slijedila je super II transportni mehanizam. Tako|er je ispitivan
u~inak neionizacijskih povr{inski aktivnih tvari Tween 80 i Span 80 na permeaciju kar-
vedilola. Rezultati su pokazali da su obje povr{inski aktivne tvari pove}ale permeaciju,
ali Span 80 vi{e. Flasteri nisu nimalo uzrokovali iritaciju ko`e.
Klju~ne rije~i: karvedilol, transdermalni flasteri, in vitro permeacija, brzina permeacije
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